Global Inherited Metabolic Disorders Testing Market – Industry Trends and Forecast to 2030

Inherited Metabolic Disorders Testing Market Analysis and Size

Growing cases of cardiomyopathy, hypertension, diabetes and hypercholesterolemia boost the metabolic syndrome market. As per the World Health Organization, at least around 2.8 million people die every year as a result of obesity, and around 17 million people die each year as a result of CVD. Factors such as increased stress in daily life & malnutrition, an adaptation of an unhealthy lifestyle, and family history of cardiac disease are also growing the market growth.

Data Bridge Market Research analyses that the inherited metabolic disorders testing market is expected to reach USD 1125.15 million by 2030, which is USD 603.4 million in 2022, and is expected to undergo a CAGR of 8.1% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Inherited Metabolic Disorders Testing Market Scope and Segmentation

Market Definition

Metabolic genetic testing is required to test the patients suffering from metabolic syndrome which are grouped diseases that occur together and surges the risk of stroke, heart disease, and type 2 diabetes. These conditions include abnormal cholesterol level, high blood sugar, excess body fat around the waist, and increased blood pressure.

Inherited Metabolic Disorders Testing Market Dynamics

Drivers

• Increasing Incidence of Metabolic Syndromes

In the recent times, it has been witnessed that the cases of diabetes have been growing, and numerous countries might face a potential metabolic disorder epidemic. Numerous industrial countries are worried with the chronic obesity epidemic, as the U.S. is ahead in the number of obese cases. The state of the economy worldwide has improved during the time, mostly in underdeveloped nations with a high frequency of metabolic illnesses. Governments are being urged by several researchers to take action and develop studies to lessen obesity and diabetes. According to the reports of CDC in 2022, around 37.3 million people have diabetes. Almost 96 million people aged 18 years or older suffer from prediabetes (approx.38.0% of the adult U.S. population) and 26.4 million people aged 65 years or older (48.8%) have prediabetes.Thus, these syndromes boost the testing market.

• Increase in Smoking Cases

In 2020, around 22.3% of the global population used tobacco, accounting for around 36.7% of all men and 7.8% of the women globally. Although certain low- and middle-income countries are witnessing a decline in smoking incidence, the emerging world is projected to continue to see a growth in smoking-related illnesses and fatalities because of the comparatively high population growth rate. In this regard, the market is increasing rapidly.

Opportunities

• Increasing Incidence of Chronic Diseases

Growing sedentary occupations, changing consumer preferences and busy lifestyles are largely affecting the world population's disease profile, particularly non-communicable diseases such as obesity and diabetes. The primary causes of metabolic disorders are decreased physical activity, and unhealthy eating habits and long working hours. According to World Health Organization (WHO) records, the incidence of chronic disease is anticipated to grow by over 57% globally, by the year 2020. Thus, this instigates the metabolic testing market.

• Increasing Launches By Several Organizations

There ve been wide and rapid launches by multiple market playersregarding the smooth testing of metabolic disorders that are boosting the market growth. For instance, Centogene N.V launched a panel for detection of rare metabolic disease in April 2019, which combines genetic and biochemical testing to offer the most comprehensive screening for rare metabolic conditions.

Restraints/Challenges

• High cost of Diagnostic Tests

There have been several tests that are immensely available for testing metabolic diseases. But these tests are of growing cost that is not afforded by several patients, mostly belonging to the lower economic groups. Therefore, it hampers the market growth.

This inherited metabolic disorders testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the inherited metabolic disorders testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Eli Lilly and Company announced the acquisition of Protomer Technologies. Protomer's proprietary peptide- and protein-engineering platform is used to detect and synthesize molecules that can sense glucose and other endogenous modulators of protein activity.
• In 2020, Lumen announced the discovery of metabolism tracking wellness device which offers real time data with person’s breath and also helps in maintaining fitness, weight loss, and others.

Global Inherited Metabolic Disorders Testing Market Scope

The inherited metabolic disorders testing market is segmented on the basis of disease type, therapy type, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Hurler Syndrome
• Niemann-Pick Disease
• Tay-Sachs Disease
• Gaucher Disease
• Fabry Disease
• Krabbe Disease
• Others

Therapy Type

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

Route of Administration

• Oral
• Parenteral
• Others

End-user

• Hospital and Clinics
• Diagnostic Laboratories
• Blood Banks
• Diagnostic Laboratories
• Others

Inherited Metabolic Disorders Testing Regional Analysis/Insights

The inherited metabolic disorders testing market is analyzed and market size insights and trends are provided by disease type, therapy type, route of administration and end-user as referenced above.

The countries covered in the inherited metabolic disorders testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the inherited metabolic disorders testing market due to the growing occurrences of metabolic disorders with increasing number of healthcare expenditure and growing awareness among the people.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the growing levels of disposable income of the people along with increasing incidences of obesity and other disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The inherited metabolic disorders testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for inherited metabolic disorders testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the inherited metabolic disorders testing market. The data is available for historic period 2011-2021.

Competitive Landscape and Global Inherited Metabolic Disorders Testing Market Share Analysis

The inherited metabolic disorders testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to inherited metabolic disorders testing market.

Some of the major players operating in the inherited metabolic disorders testing market are:

• Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
• MGC Diagnostics Corporation (U.S.)
• Abbott (U.S.)
• Promega Corporation (U.S.)
• Alomone Labs (Israel)
• Bio-Rad Laboratories, Inc. (U.S.)
• Novartis AG (Switzerland)
• AstaReal (Sweden)
• Regeneron Pharmaceuticals Inc (U.S.)
• Biophytis (U.K.)
• AbbVie Inc. (U.S.)
• Danone S.A. (France)
• Pfizer Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Bristol Myers Squibb Company (U.S.)
• Biogen (U.S.)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)

SKU-57118